Videos

AMD Fluid Resolution

Symposium:

Optimising Real World Outcomes in nAMD Treatment
Interview 1

Best Practices for Diagnosing & Monitoring AMD
Interview 2

Outcome Goals for Anti-VEGF Treatment
Interview 3

nAMD Treatment Protocols & Therapy Decisions

Podcasts

Podcasts

Part 1

Best practices for diagnosing & monitoring AMD
In the first episode of the EURETINA podcast series on AMD Fluid Resolution Drs. Ramin Tadayoni and Sebastian Wolf talk about best practices for diagnosing & monitoring AMD. To hear the entire interview, make sure to listen to the remaining two podcasts in this series. Independent medical education support provided by Novartis and Zeiss.

Podcasts

Part 2

Outcome goals for anti-VEGF treatment in nAMD patients
In the second episode of the EURETINA podcast series on AMD Fluid Resolution Drs. Ramin Tadayoni and Sebastian Wolf discuss outcome goals for anti-VEGF treatment in nAMD patients. To hear the entire interview, make sure to listen to the remaining two podcasts in this series. Independent medical education support provided by Novartis and Zeiss.

Podcasts

Part 3

nAMD treatment protocols and therapy decisions
In the third episode of the EURETINA podcast series on AMD Fluid Resolution Drs. Ramin Tadayoni and Sebastian Wolf talk about nAMD treatment protocols and therapy decisions. To hear the entire interview, make sure to listen to the remaining two podcasts in this series. Independent medical education support provided by Novartis and Zeiss.

Supplements

eLearning

Best Practices for Diagnosing and Monitoring nAMD

This short course examines best practises for diagnosing and monitoring AMD, using multimodal imaging, as well as the use of AI in the analysis of data attained.

Real-world Experience with New Anti-VEGFs

This module considers real-world experience with anti-VEGF therapies for patients with AMD, covering patient adherence, the consequences of undertreatment and discussing ways to incorporate new anti-VEGFs into treatment.

nAMD Patient Selection and Outcome Goals for anti-VEGF Treatment

This short course examines the evidence from several trials to better understand the importance of fluid type and their effect on treatment decision making and long-term outcomes in nAMD patients.

Independent medical education support provided by
Novartis* | ZEISS

* This Activity is Funded by Novartis.

All content has been developed independently by EURETINA and Novartis has had no editorial control in the development of the same.